{"organizations": [], "uuid": "c0cb9e4b9cd5c87d2a4dd53347ec7269afb6fff2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rocket-pharmaceuticals-presents-up/brief-rocket-pharmaceuticals-presents-updated-data-from-phase-1-2-gene-therapy-trial-of-rp-l102-idUSASC0A2YH", "country": "US", "domain_rank": 408, "title": "BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-19T04:22:00.000+03:00", "replies_count": 0, "uuid": "c0cb9e4b9cd5c87d2a4dd53347ec7269afb6fff2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rocket-pharmaceuticals-presents-up/brief-rocket-pharmaceuticals-presents-updated-data-from-phase-1-2-gene-therapy-trial-of-rp-l102-idUSASC0A2YH", "ord_in_thread": 0, "title": "BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102", "locations": [], "entities": {"persons": [{"name": "hase", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "rocket pharmaceuticals inc", "sentiment": "negative"}, {"name": "gene therapy trial of rp-l102", "sentiment": "negative"}, {"name": "anemia", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18 (Reuters) - Rocket Pharmaceuticals Inc:\n* ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING\n* ROCKET PHARMACEUTICALS - CONTINUED CLINICAL EVIDENCE DEMONSTRATES RP-L102 CAN RESTORE BONE MARROW FUNCTION OF FANCONI ANEMIA PATIENTS WITHOUT CONDITIONING\n* ROCKET PHARMACEUTICALS INC - ALL PATIENTS DEMONSTRATED CONTINUED IMPROVEMENT IN ENGRAFTMENT FOLLOWING ADMINISTRATION OF RP-L102 IN TRIAL\n* ROCKET PHARMACEUTICALS INC - NO SERIOUS DRUG-RELATED ADVERSE EVENTS HAVE BEEN OBSERVED TO DATE IN TRIAL\n* ROCKET PHARMACEUTICALS INC - ADDITIONAL PATIENT DATA FROM FA PROGRAM IS EXPECTED OVER NEXT 12-18 MONTHS\n* ROCKET PHARMACEUTICALS - ROCKET WILL ENGAGE WITH REGULATORY AUTHORITIES TO PROGRESS RP-L102 TOWARDS A POTENTIAL GLOBAL REGISTRATIONAL STUDY IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-19T04:22:00.000+03:00", "crawled": "2018-05-19T15:36:13.009+03:00", "highlightTitle": ""}